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In this study, we compared the effects of altered membrane lipid composition on the localization of two
membrane drug transporters from different superfamilies of the pathogenic yeast Candida albicans. We
demonstrated that in comparison to the major facilitator superfamily multidrug transporter CaMdr1p,
ATP-binding cassette transporter CaCdr1p of C. albicans is preferentially localized within detergent-resistant
membrane (DRM) microdomains called ‘rafts.’ Both CaCdr1p and CaMdr1p were overexpressed as green
fluorescent protein (GFP)-tagged proteins in a heterologous host Saccharomyces cerevisiae, wherein either
sphingolipid (sur4 or fen1 or ipt1) or ergosterol (erg24 or erg6 or erg4) biosynthesis was compromised.
CaCdr1p-GFP, when expressed in the above mutant backgrounds, was not correctly targeted to plasma
membranes (PM), which also resulted in severely impaired drug resistance. In contrast, CaMdr1p-GFP
displayed no sorting defect in the mutant background and remained properly surface localized and displayed
no change in drug resistance. Our data clearly show that CaCdr1p is selectively recruited, over CaMdr1p, to
the DRM microdomains of the yeast PM and that any imbalance in the raft lipid constituents results in
missorting of CaCdr1p.
In pathogenic as well as nonpathogenic yeasts, several mech-
anisms can contribute to the development of multidrug resis-
tance (MDR). Point mutations or overexpression of the drug
target, a decrease in the import of drugs, and an enhanced
efflux of drugs are some of the strategies employed by drug-
resistant yeast to overcome the lethal effects of the drugs (4, 8,
39, 40). However, extrusion of noxious compounds from the
cell, mediated by efflux pumps, is one of the most frequently
used strategies for the development of drug resistance in
yeasts, which holds true for several prokaryotic and eukaryotic
organisms (38, 41, 48).
The two major efflux pump proteins involved in MDR be-
long to ATP-binding cassette (ABC) and major facilitator
(MFS) superfamilies. Genome analysis of Saccharomyces cer-
evisiae and of the pathogenic yeast Candida albicans reveal the
existence of 30 and 28 putative ABC transporters, respectively,
of which only a few function as drug transporters (9, 17).
Similar to the ABC protein superfamily, very few members of
the MFS family are drug exporters. For example, out of 62
putative transporters in S. cerevisiae (6), only FLR1 (flucon-
azole resistance) has been shown to confer resistance to drugs
(7). In pathogenic C. albicans, out of 71 MFS proteins, only
CaMDR1 is known to extrude drugs, where its overexpression
has been linked to azole resistance (6, 35).
The efflux pumps CaCdr1p and CaMdr1p are both localized
on the plasma membrane (PM) (35, 43). Interestingly,
CaCdr1p is sensitive to changes in the membrane environment
and also plays a role in maintaining membrane asymmetry (24,
32, 34, 37, 44). Human Pgp/MDR1, a homologue of the yeast
ABC proteins, is predominantly localized in microdomains
within the PM. The presence of the microdomains, also called
‘lipid rafts,’ in various organisms plays an important role in cell
signaling, protein sorting, and virulence (13, 29, 30, 31, 36, 47).
Lipid rafts are highly enriched in sphingolipid and ergosterol
or cholesterol and are characterized by their insolubility in
detergent (1, 2, 15, 22). Depletion of cholesterol from these
domains impairs Pgp-mediated drug transport in a substrate-
and cell-type-specific manner (11). It is also observed that
human Pgp/MDR1 contributes to stabilize the cholesterol-rich
microdomains by mediating cholesterol redistribution within
the cell membrane (16). The acquisition of the MDR pheno-
type in certain mammalian cell lines is not only due to over-
expression of the drug efflux pumps but is also accompanied by
an upregulation of genes required for normal lipid metabolism
that constitute membrane rafts (26). In yeasts as well, we have
previously shown that efflux pump proteins, particularly of the
ABC superfamily, are influenced by imbalances in membrane
lipid composition (32, 34, 37, 44). The presence of detergent-
resistant membranes (DRMs) within the yeast PM has recently
been demonstrated (29, 46). In order to critically evaluate the
role of the DRM lipid constituents in the localization of the
efflux pumps, in this study, we have overexpressed green fluo-
rescent protein (GFP)-tagged CaCdr1p and CaMdr1p in dif-
ferent lipid mutant backgrounds of S. cerevisiae. The mutants
used were defective either in the ergosterol (erg24 or erg6 or
erg4) or in the sphingolipid (sur4 or fen1 or ipt1) biosyn-
thesis pathway.
Here we report that the observed abrogated functioning of
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CaCdr1p in the various mutant backgrounds is mainly due to
its missorting, resulting in poor localization in the PM.
CaMdr1p interestingly remains unaffected by the defects in the
mutant strains. Our study clearly establishes that out of the two
different classes of multidrug transporters, only one (CaCdr1p)
is exclusively directed to the membrane rafts for proper local-
ization and functioning. Coupled together, it appears that
membrane sphingolipid and sterols as individual components
as well as their mutual interactions are critical in sorting and
functioning of the ABC efflux pump protein of yeasts.
MATERIALS AND METHODS
Materials. Media chemicals were obtained from Difco (BD Biosciences) and
HiMedia (Mumbai, India). The drugs cycloheximide (CYH), 4-nitroquinoline-
N-oxide (4-NQO), methotrexate (MTX), cerulenin (CER), and Geneticin
(G418) and the protease inhibitors (phenylmethylsulfonyl fluoride, leupeptin,
pepstatin A, and aprotinin) and Optiprep were obtained from Sigma Chemical
Co. (St. Louis, MO). Anti-GFP monoclonal antibody was purchased from BD
Biosciences (Clontech, Palo Alto, CA). 3H-fluconazole (FLC) was custom pre-
pared, and 3H-methotrexate (MTX) was procured from Amersham Biosciences,
United Kingdom. Fluconazole was a kind gift from Ranbaxy Laboratories (New
Delhi, India).
Bacterial and yeast strains and growth media. Plasmids were maintained in
Escherichia coli DH-5. E. coli was cultured in Luria-Bertani medium (Difco, BD
Biosciences), to which ampicillin was added (100 g/ml). The yeast strains used
in this study are listed in Table 1. The strains (AD1-8u [10], PSCDR1-GFP
[AD1-8u derivative expressing CaCdr1p-GFP] [43], RPCaMDR1-GFP [AD1-
8u derivative expressing CaMdr1p-GFP] [35]) and the deletion mutants ex-
pressing either CaCdr1p-GFP or CaMdr1p-GFP were grown in yeast extract-
peptone-dextrose (YEPD) broth (Bio101, Vista, CA), complete synthetic
medium (CSM), or in SD Ura drop-out media (0.67% yeast nitrogen base, 0.2%
drop-out mix, and 2% glucose; Difco). G418-resistant yeast colonies were se-
lected on YEPD/G418 medium or CSM/G418 medium. For agar plates, 2.5%
(wt/vol) Bacto agar (Difco, BD Biosciences) was added to the medium.
Disruption of ergosterol and sphingolipid biosynthetic genes. For disruption
of ergosterol biosynthesis genes, which include ERG24 (YNL280C), ERG6
(YML008C), and ERG4 (YGL012W), and sphingolipid biosynthesis genes,
which include SUR4 (YLR372W), FEN1 (YCR034W), and IPT1 (YDR072C),
the corresponding disruption cassettes (deletion mutant fused with kanMX4)
were amplified by PCR from the yeast knockout library (the Open Biosystems
Mata haploid set [http://sequence-www.stanford.edu/group/yeast_deletion
_project/deletions3.html]) (Fig. 1E). The oligonucleotides used for amplification
are listed in Table 2. Purified PCR fragments were transformed into PSCDR1
-GFP and RPCaMDR1-GFP by the lithium acetate transformation protocol (18)
and selected on plates containing G418 (250 g/ml), to obtain the strains
mentioned in Table 1. The correct integration of the disruption cassette in the
target gene was confirmed by PCR (data not shown). Proper expression of the
protein in these lipid knockouts was also confirmed by Western blotting
(discussed below).
Drug susceptibility assay. The various mutant strains were tested for their
susceptibility to several drugs by spot assays. Freshly streaked cells were grown
overnight suspended in normal saline to an optical density at 600 nm (OD600) of
0.1 (0.1 OD corresponds to 1 106 cells/ml of yeast cells). Five microliters of
fivefold serial dilutions of 0.1 OD of each yeast culture suspension was spotted
at the following concentrations: 1:5 dilution (200,000 cells), 1:25 dilution (40,000
cells), 1:125 dilution (8,000 cells), and 1:625 dilution (1,600 cells). These were
spotted onto agar plates in the absence (control) or in the presence of the drugs
(35).
Drug transport. Accumulation of 3H-MTX (specific activity, 8.60 Ci/mmol)
and 3H-FLC (specific activity, 19 Ci/mmol) was determined essentially by the
protocol described previously (35). For accumulation assays, 25 M of 3H-MTX
and 100 nM of 3H-FLC was routinely used.
Confocal microscopy and flow cytometry. Confocal imaging and flow cytom-
etry (fluorescence-activated cell sorter [FACS]) analysis of CaCdr1p-GFP,
CaMdr1p-GFP, and lipid mutants expressing these two proteins were performed
under an oil immersion objective at 100 magnification on a confocal micro-
scope (Radiance 2100, AGR, 3Q/BLD; Bio-Rad, United Kingdom) and a
FACSort flow cytometer (Becton-Dickson Immunocytometry Systems, San Jose,
CA) as described previously (43).
Immunodetection of CaCdr1p and CaMdr1p. Purified PM fractions of yeast
cells were prepared as described previously (43). The PM protein concentration
was determined by bicinchoninic acid assay using bovine serum albumin as the
standard. Forty micrograms of each PM protein sample was electrophoresed by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), trans-
ferred to nitrocellulose membrane, and Western blotted using primary mono-
clonal -GFP (1:5,000) (BD Biosciences) or polyclonal -Pma1p antibody for
PM-ATPase (1:1,000) antibody (provided by R. Serrano). Primary antibodies
were detected with horseradish peroxidase-conjugated secondary antibody (1:
5,000), followed by detection of chemiluminescence (ECL kit; Amersham) (43).
Isolation of membrane rafts. Lipid rafts were isolated according to the method
of Bagnat et al. (2), with the following modification: crude membranes, instead
of the whole-cell extract, were used for the detergent extraction analysis. An
amount of cells equivalent to 100 OD600 units of an overnight culture was broken
by vortexing with glass beads in TNE buffer (50 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 5 mM EDTA) supplemented with leupeptin (4 M) and pepstatin (2 M).
TABLE 1. List of yeast strains used in this study
Strain Genotype Source or reference
AD1–8u Mata pdr1-3 his1 ura3 yor1::hisG snq2::hisG pdr5::hisG pdr10::hisG
pdr11::hisG ycf1::hisG pdr3::hisG pdr15::hisG
10
PSCDR1-GFP AD1–8u cells harboring CaCDR1-GFP ORF integrated at PDR5 locus 43
RPCaMDR1-GFP AD1–8u cells harboring CaMDR1-GFP ORF integrated at PDR5 locus 35
YGL012W erg4 BY4742 except erg4::kanMX4 Open Biosystems
YDR072C ipt1 BY4742 except ipt1::kanMX4 Open Biosystems
YML008C erg6 BY4742 except erg6::kanMX4 Open Biosystems
YNL280C erg24 BY4742 except erg24::kanMX4 Open Biosystems
YCR034W fen1 BY4742 except fen1::kanMX4 Open Biosystems
YLR372W sur4 BY4742 except sur4::kanMX4 Open Biosystems
sur4/CaCDR1-GFP sur4 strain expressing CaCdr1p-GFP at PDR5 locus This study
fen1/CaCDR1-GFP fen1 strain expressing CaCdr1p-GFP at PDR5 locus This study
erg6/CaCDR1-GFP erg6 strain expressing CaCdr1p-GFP at PDR5 locus This study
erg24/CaCDR1-GFP erg24 strain expressing CaCdr1p-GFP at PDR5 locus This study
ipt1/CaCDR1-GFP fen1 strain expressing CaCdr1p-GFP at PDR5 locus This study
erg4/CaCDR1-GFP erg4 strain expressing CaCdr1p-GFP at PDR5 locus This study
sur4/CaMDR1-GFP sur4 strain expressing CaMdr1p-GFP at PDR5 locus This study
fen1/CaMDR1-GFP fen1 strain expressing CaMdr1p-GFP at PDR5 locus This study
erg6/CaMDR1-GFP erg6 strain expressing CaMdr1p-GFP at PDR5 locus This study
erg24/CaMDR1-GFP erg24 strain expressing CaMdr1p-GFP at PDR5 locus This study
ipt1/CaMDR1-GFP ipt1 strain expressing CaMdr1p-GFP at PDR5 locus This study
erg4/CaMDR1-GFP erg4 strain expressing CaMdr1p-GFP at PDR5 locus This study
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FIG. 1. (A) Differential interference contrast (DIC) (right panels) and confocal (left panels) images of the control AD1-8u, PSCDR1-GFP
(AD1-8u expressing CaCdr1p-GFP), and RPCaMDR1-GFP (AD1-8u expressing CaMdr1p-GFP) strains. Both GFP-tagged proteins showed
typical rimmed appearance on the periphery of the cells. (B) PM protein (40 g) from each strain was loaded on the SDS-PAGE gel and
electrophoresed for Western blotting. The GFP-tagged proteins in the strains AD1-8u (control strain, lane 1 in both panels), PSCDR1-GFP (lane
2, upper panel), and RPCaMDR1-GFP (lane 2, lower panel) were detected with -GFP primary monoclonal antibody, showing that the proteins
are properly expressed and targeted. Primary antibodies were detected with horseradish peroxidase-conjugated secondary antibody, followed by
detection of chemiluminescence (ECL kit; Amersham) (43). (C) Spot assays, showing the pattern of drug resistance of AD1-8u, PSCDR1-GFP,
and RPCaMDR1-GFP strains. Cells were resuspended in normal saline to an OD600 of 0.1 (0.1 OD corresponding to 1 10
6 cells/ml). Five
microliters of fivefold serial dilutions of 0.1 OD culture of each yeast strain suspension was then spotted in concentrations of 1:5 (1), 1:25 (2), 1:125
(3), and 1:625 (4) on agar plates in the absence (control) and the presence of various drugs: FLC (0.17 g/ml), CYH (0.2 g/ml), CER (3 g/ml),
4-NQO (0.2 g/ml), and MTX (65 g/ml). Growth differences were recorded following incubation of the plates for 48 h at 30°C. (D) Plates showing
sensitivity of the PSCDR1-GFP and RPCaMDR1-GFP strains for G418, which is used as the selection marker for transformation, while the lipid
knockout mutants from the yeast knockout library are resistant to G418. (E) Strategy for the disruption of the genes involved: PCR amplification
of the disruption cassette with homology to the region flanking the ORFs of the gene to be disrupted with G418 as the selection marker (deletion
mutant fused with kanMX4) (5, 45), followed by integration of the amplicon by the lithium acetate transformation protocol (18).
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After low-speed centrifugation, crude membranes were collected by centrifuga-
tion (30 min at 58,000  g; Beckman Ti 70.1 rotor at 4°C). Aliquots of crude
membranes (200 g of total protein) were resuspended in 270 l of TNE buffer.
Triton X-100 was added to a final concentration of 1%, and the mixture was
incubated for 30 min on ice. Then, Optiprep (Sigma) was added to a final concen-
tration of 40% (wt/vol). The samples transferred to centrifuge tubes were overlaid
with 1.32 ml of 30% Optiprep in TXNE (TNE plus 0.1% Triton X-100) followed by
220 l of TXNE and were centrifuged for 2 h at 259,000  g in a Beckman TLS55
rotor at 4°C. Six equal fractions were collected from the top of each gradient, where
the proteins were precipitated with trichloroacetic acid (final concentration, 10%)
and collected by centrifugation at 4°C. This step was required to prevent proteolysis
by residual endogeneous proteases. The pellets were neutralized by and dissolved in
10l of 1 M Tris base and 25l of dissociation buffer (0.1 M Tris-HCl, pH 6.8, 4 mM
EDTA, 4% SDS, 20% glycerol, 2% 2-mercaptoethanol, 0.02% bromphenol blue).
The samples were incubated at 37°C for 15 min and analyzed by SDS-PAGE and
immunoblotting as described above.
FIG. 2. (A) Schematic representation of the ergosterol biosynthetic pathway. The genes disrupted are shown with a cross in the pathway.
Disrupted genes include the following: ERG24, ERG6, and ERG4. (B and C) Spot assays with AD1-8u, PSCDR1-GFP, RPCaMDR1-GFP, and
ergosterol mutants (erg24, erg6, and erg4) expressing CaCdr1p or CaMdr1p-GFP. Cells were freshly streaked and grown overnight and were
resuspended in normal saline to an OD600 of 0.1 (0.1 OD corresponding to 1 10
6 cells/ml). Five microliters of fivefold serial dilutions of 0.1 OD
culture of each yeast strain suspension was then spotted in concentrations of 1:5, 1:25, 1:125, and 1:625 on agar plates containing different drugs:
FLC (0.17 g/ml), CYH (0.2 g/ml), CER (3 g/ml), 4-NQO (0.2 g/ml), and MTX (65 g/ml). Growth differences were recorded following
incubation of the plates for 48 h at 30°C.
TABLE 2. List of the oligonucleotides used in this study
Primer Sequence Purpose
F1AMP 5-TGGTCCTGCTATCATGCTATTG-3 Forward primer for amplifying erg4::kanMX4
R1AMP 5-AATGGCTAACCTTTCCCAAATC-3 Reverse primer for amplifying erg4::kanMX4
F11AMP 5-CCTCTGATTGTGCTGATTGATTC-3 Forward primer for amplifying ipt1::kanMX4
R11AMP 5-TCTGAAGCTCTTTCGTTTGGTG-3 Reverse primer for amplifying ipt1::kanMX4
ERG6-F 5-CCGATAACTTCTTCATTGCTT-3 Forward primer for amplifying erg6::kanMX4
ERG6-R 5-CTGATAGAAAATACTGGTCGT-3 Reverse primer for amplifying erg6::kanMX4
ERG24-F 5-CATTGTGTGAAGGTTGTGCAT-3 Forward primer for amplifying erg24::kanMX4
ERG24-R 5-AGCGTTGCATAGATAGACCAC-3 Reverse primer for amplifying erg24::kanMX4
FEN1-F 5-GAAAATCGCAAAACCCACAG-3 Forward primer for amplifying fen1::kanMX4
FEN1-R 5-CTAAAATAACGCCAGAAATG-3 Reverse primer for amplifying fen1::kanMX4
SUR4-F 5-TGGAGTCTTCTGTTTGTTGTT-3 Forward primer for amplifying sur4::kanMX4
SUR4-R 5-GGACACTTTACAAACTGCAAG-3 Reverse primer for amplifying sur4::kanMX4
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RESULTS
Overexpression of GFP-tagged CaCdr1p and CaMdr1p. In this
study, we exploited the well-established and extensively used ex-
pression system of S. cerevisiae for the overexpression of CaCdr1p
and CaMdr1p (10, 25, 35, 42, 43). The strategy of GFP tagging
and cloning of CaCdr1p and CaMdr1p in the plasmid pSK-
PDR5PPUS was described previously (35, 43). The rimmed ap-
pearance of strains expressing GFP-tagged CaCdr1p (PSCDR1-
GFP) and CaMdr1p (RPCaMDR1-GFP) under confocal
microscopy and Western blot analysis of the PM fractions of the
strains confirmed their proper expression and surface localization
(Fig. 1A and B). Spot assays for drug susceptibility revealed that
both the proteins are fully functional (Fig. 1C).
Deletion of ergosterol and sphingolipid biosynthetic genes.
PSCDR1-GFP and RPCaMDR1-GFP (AD1-8u derivatives
expressing CaCdr1p and CaMdr1p, respectively) were tested
for their sensitivity to the drug G418, which is the selectable
marker of the ‘yeast knockout’ (YKO) collection of S. cerevi-
siae (Open Biosystems Mata haploid set) (Fig. 1D). Both
PSCDR1-GFP and RPCaMDR1-GFP strains were sensitive to
G418 (Fig. 1D). The knockout was based on a PCR-generated
deletion strategy, which was used to systematically replace the
yeast open reading frame (ORF) from its start to stop codon
with a kanMX4 module (5, 45). The disruption cassette with
homology to the region flanking the ORFs of the gene to be
disrupted and with G418 as the selection marker was amplified
(Fig. 1E), and the amplicon was purified and transformed by
the lithium acetate transformation protocol (18). The integra-
tion of the disruption cassette at the right locus was confirmed
by PCR (data not shown). The genes disrupted in the sphin-
golipid biosynthesis pathway in PSCDR1-GFP and RPCaMDR1-
GFP included the following: FEN1, which codes for fatty acid
elongase and acts on fatty acids of up to 24 carbons in length
(fen1/CaCDR1-GFP and fen1/CaMDR1-GFP); SUR4,
which also codes for an elongase, involved in fatty acid and
sphingolipid biosynthesis and synthesizes very-long-chain, 20-
to 26-carbon fatty acids from C-18–coenzyme A primers
(sur4/CaCDR1-GFP and sur4/CaMDR1-GFP); and IPT1,
which codes for inositol phosphotransferase 1, involved in syn-
thesis of mannose-(inositol-P)2-ceramide [M(IP)2C] (ipt1/
CaCDR1-GFP and ipt1/CaMDR1-GFP). In the ergosterol
biosynthesis pathway, we disrupted the following genes:
FIG. 3. (A) Schematic representation of the sphingolipid biosynthetic pathway in fungi. The disrupted genes FEN1, SUR4, and IPT1 are shown
with a cross in the pathway. (B and C) Spot assays with AD1-8u, PSCDR1-GFP, RPCaMDR1-GFP, and sphingolipid mutants (fen1, sur4, or
ipt1) expressing CaCdr1p-GFP or CaMdr1p-GFP. Five-microliter samples of fivefold serial dilutions of each yeast culture (each with cells
suspended in normal saline to an OD600 of 0.1) (0.1 OD corresponding to 1 10
6 cells/ml) were spotted onto agar plates in the absence (control)
or in the presence of the following drugs (35): FLC (0.17 g/ml), CYH (0.2 g/ml), CER (3 g/ml), 4-NQO (0.2 g/ml), and MTX (65 g/ml).
Growth differences were recorded following incubation of the plates for 48 h at 30°C.
698 PASRIJA ET AL. ANTIMICROB. AGENTS CHEMOTHER.
ERG24, which codes for C-14 sterol reductase (erg24/
CaCDR1-GFP and erg24/CaMDR1-GFP); ERG6, which
codes for (24)-sterol C-methyltransferase (erg6/CaCDR1-
GFP and erg6/CaMDR1-GFP); and ERG4, which encodes
for sterol C-24(28) reductase (erg4/CaCDR1-GFP and erg4/
CaMDR1-GFP) (Table 1). The respective positions of all these
genes in the ergosterol and sphingolipid biosynthetic pathways
are shown in Fig. 2A and 3A, respectively.
FIG. 4. 3H-MTX and 3H-FLC accumulation in PSCDR1-GFP and lipid mutants expressing CaCdr1p-GFP. 3H-FLC (A) and 3H-MTX
(B) accumulation in sphingolipid mutants sur4, fen1, and ipt1 and ergosterol mutants erg6, erg24, and erg4, expressing CaCdr1p-GFP.
AD1-8u is shown as the control. The values plotted are from 10 min after commencement of transport. The results are the means  standard
deviations of three independent experiments.
FIG. 5. 3H-MTX and 3H-FLC accumulation in RPCaMDR1-GFP and lipid mutants expressing CaMdr1p-GFP. Accumulation of 3H-FLC (A) and
3H-MTX (B) for sphingolipid mutants sur4, fen1, and ipt1 and ergosterol mutants erg6, erg24, and erg4, expressing CaMdr1p-GFP. The values
plotted are from 10 min after commencement of transport. The results are the means  standard deviations of three independent experiments.
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CaCdr1p-mediated drug resistance depends on the mem-
brane lipid status. To analyze the activity of CaCdr1p-GFP-
and CaMdr1p-GFP-expressing strains in the ergosterol and
sphingolipid biosynthetic mutant backgrounds, the strains were
tested for their susceptibility to different drug substrates by
spot assays. In comparison to the highly sensitive AD1-8u
cells (Fig. 1C), which showed almost no growth in the presence
of the drugs, cells expressing wild-type CaCdr1p-GFP
(PSCDR1-GFP) (43) and CaMdr1p-GFP (RPCaMDR1-GFP)
(35) were able to tolerate the same concentrations of all the
tested drugs, such as FLC, CYH, MTX, 4-NQO, and CER.
Thus, all the tested drugs are substrates of CaCdr1p as well as
of CaMdr1p. We had previously observed that although both
FLC and MTX can be transported by CaCdr1p and CaMdr1p,
the former is a better substrate of CaCdr1p while the latter is
a preferred substrate of CaMdr1p (35).
Overexpression of CaCdr1p-GFP in ergosterol (erg24/
CaCDR1-GFP, erg6/CaCDR1-GFP, and erg4/CaCDR1-
GFP) (Fig. 2B) or sphingolipid (sur4/CaCDR1-GFP, fen1/
CaCDR1-GFP, and ipt1/CaCDR1-GFP) (Fig. 3B) knockout
strains resulted in hypersensitivity to drugs. In contrast, no
abrogation of drug resistance was observed in CaMdr1p-GFP
when expressed in the above null mutants (Fig. 2C and 3C).
These results were also confirmed by the microdilution method
(data not shown).
Notably, erg4 and ipt1 mutants expressing CaCdr1p were
relatively less sensitive to all the tested drugs than were the
other knockout mutants. Both ERG4 and IPT1 catalyze the last
step in the ergosterol and sphingolipid biosynthesis pathways,
respectively, and the absence of these in ipt1 and erg4 cells
selectively prevents the formation of the end product, though
the precursors of the pathway are still present. These precur-
sors are probably able to compensate for the absence of er-
gosterol or M(IP)2C on the membrane. Additionally, both
CaCdr1p and CaMdr1p proteins, as revealed by Western blot-
ting and confocal images, are not totally mislocalized in ipt1
and erg4 cells, which again could contribute to the observed
resistance to all the drugs.
The efflux of MTX and FLC mediated by CaCdr1p-GFP was
severely hampered in lipid mutants. In order to correlate
CaCdr1p-GFP-mediated drug sensitivity to the reduced efflux
of drugs in the ergosterol and sphingolipid mutant back-
grounds, accumulation of two radiolabeled drug substrates
such as 3H-MTX and 3H-FLC was measured. An increase or
decrease in the level of accumulation of the drug, at a given
time point, implies its reduced or enhanced efflux, respectively.
It is apparent from Fig. 4 and 5 that, compared to the host
(AD1-8u) cells, the accumulation of 3H-MTX and 3H-FLC
was considerably reduced (more efflux) in cells expressing
CaCdr1p-GFP- and CaMdr1p-GFP-tagged proteins. We ex-
amined the efflux activity of CaCdr1p-GFP in the lipid null
mutant backgrounds by measuring the accumulation of drug
substrates in cells expressing CaCdr1p-GFP, namely, sur4/
CaCDR1-GFP, fen1/CaCDR1-GFP, erg6/CaCDR1-GFP,
FIG. 6. (A) Immunodetection of CaCdr1p in the PM of strain PSCDR1-GFP and lipid mutants expressing CaCdr1p-GFP. PM protein (40 g)
from each strain was electrophoresed on SDS-PAGE, transferred to nitrocellulose, and Western blotted. The presence of the GFP-tagged
CaCdr1p was detected by immunoblotting with -GFP monoclonal primary antibody and detected with horseradish peroxidase-conjugated
secondary antibody, followed by detection of chemiluminescence (ECL kit; Amersham) (43). WT, wild type. (B) Fluorescence imaging (upper
panel) by confocal microscopy shows membrane localization of CaCdr1p-GFP. Flow cytometry (lower panel) of S. cerevisiae expressing CaCdr1p-
GFP and lipid mutants expressing GFP-tagged CaCDR1. The histogram derived from the Cell Quest program depicts the total fluorescence
intensities of AD1-8u (control) (purple filled area) and PSCDR1-GFP (solid pink line) for each panel, and the other extra line (solid green)
represents those of the respective lipid mutant variants expressing CaCdr1p-GFP.
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erg24/CaCDR1-GFP, ipt1/CaCDR1-GFP, and erg4/
CaCDR1-GFP. The accumulation was significantly increased
(decrease in efflux) for FLC (between 24 and 57%) and for
MTX (between 13 and 35%), compared with the accumulation
of these drugs in normal cells expressing CaCdr1p-GFP (Fig.
4A and B). In comparison, CaMdr1p-GFP, when expressed in
the same backgrounds, showed no significant difference in its
ability to efflux both the drugs (Fig. 5A and B). In general, the
accumulation data matched well with the level of sensitivity
observed for the drugs. For example, among ergosterol mu-
tants, erg24 and erg6 are more sensitive to drugs than erg4
cells, and this difference is also reflected in the accumulation of
FLC and MTX, wherein sensitive erg24 and erg6 strains
accumulate much higher levels (reduced efflux) of drug than
the less-sensitive erg4 mutant cells. This is also true for ipt1
versus fen1 and sur4. The sensitive fen1 and sur4 show
much higher accumulation of the drug than the ipt1 cells.
Lipid imbalance caused selective recruitment defect of
CaCdr1p-GFP. We also examined the effect of lipid changes
on CaCdr1p-GFP localization in the PM. Immunoblot results
demonstrated that between CaMdr1p and CaCdr1p (Fig. 6 and
Fig. 7), the expression of the latter in the PM was considerably
reduced in most of the ergosterol (erg6/CaCDR1-GFP,
erg24/CaCDR1-GFP, and erg4/CaCDR1-GFP) and sphin-
golipid (sur4/CaCDR1-GFP, fen1/CaCDR1-GFP, and
ipt1/CaCDR1-GFP) null mutants compared to that in control
cells expressing CaCdr1p-GFP (Fig. 6A). Confocal images of
CaCdr1p-GFP in the null mutants also showed poor surface
localization, as was evident from the lack of total rimmed
appearance on the periphery of the cells and trapped GFP
fluorescence inside the cells (Fig. 6B, C, and D, upper panels).
Results obtained from FACS analyses also showed reduced
total fluorescence, which was consistent with the immunoblot
and confocal data confirming poor expression of CaCdr1p in
the PM (Fig. 6C and D, lower panels). Interestingly, the char-
acteristic distribution of CaCdr1p in DRMs was lost in all the
lipid mutants (Fig. 8D). However, in the erg6 mutant, similar
to the control strain (top panel), CaCdr1p protein is visible in
fractions 1 and 2, but unlike the control strain, a majority of
CaCdr1p was present in fractions 5 and 6. Thus, mislocaliza-
tion of CaCdr1p in erg6 did not appear to be complete, as was
the case with other mutants. Notwithstanding this, erg6 mu-
tation was sufficient to result in mislocalization of a majority of
CaCdr1p.
CaCdr1p is localized in membrane rafts. Ergosterol and
sphingolipids are major constituents of lipid rafts, also called
DRMs for their property of being resistant to solubilization
when treated with nonionic detergents at low temperature (1,
2, 15, 22). Since we observed that CaCdr1p is mislocalized
following imbalances in raft lipid constituents, we checked if
CaCdr1p is associated with these discrete DRMs. For this, we
isolated membrane rafts by the detergent insolubility method
using the nonionic detergent Triton X-100 (2, 12, 21, 28, 31) as
described in Materials and Methods. We used Optiprep for
FIG. 7. (A) Immunodetection of CaMdr1p in the PM of strain RPCaMDR1-GFP and lipid mutants expressing CaMdr1p-GFP. PM protein
samples (40 g) from each strain were electrophoresed through SDS-PAGE and analyzed by Western blotting with -GFP monoclonal primary
antibody. Primary antibodies were detected with horseradish peroxidase-conjugated secondary antibody, followed by detection of chemilumines-
cence (ECL kit; Amersham) (43). WT, wild type. (B) Fluorescence imaging (upper panel) by confocal microscopy showing membrane localization
of CaMdr1p-GFP. Flow cytometry (lower panel) of S. cerevisiae expressing CaMdr1p-GFP and lipid mutants expressing GFP-tagged CaMDR1. The
histogram derived from the Cell Quest program depicts the total fluorescence intensities of AD1-8u (control) (purple filled area) and
RPCaMDR1-GFP (solid green line) for each panel, and the other extra line (solid pink) represents those of the respective lipid mutant variants
expressing CaMdr1p-GFP.
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gradient formations wherein DRM generally constitutes the
upper two fractions, when six equal fractions from top to bot-
tom are taken (12, 21, 28) (Fig. 8A). Immunoblot analysis with
monoclonal -GFP primary antibody of the DRM fractions
clearly showed the presence of CaCdr1p in the top two floating
raft fractions (Fig. 8D, first panel). The raft preparation was
verified by reprobing the immunoblot with the polyclonal
-Pma1p secondary antibody (Fig. 8C), which is a positive
marker for raft proteins (1, 2, 19). The MFS transporter
CaMdr1p, on the other hand, was not exclusively present in
raft fractions but rather was evenly distributed in all the frac-
tions. This distribution pattern of CaMdr1p remained unaf-
fected by the lipid perturbations (Fig. 8E).
DISCUSSION
Our results show that the cells expressing the ABC trans-
porter CaCdr1p in lipid mutants (either defective in sphingo-
lipid or ergosterol biosynthesis) turned sensitive to the tested
drugs, which was also evident from their abrogated efflux of
drug substrates. In comparison, cells expressing the MFS trans-
porter CaMdr1p in the same lipid mutant background re-
mained properly surface localized, displayed resistance to
drugs, and showed unaltered efflux of drug substrates. Taken
together, both ergosterol and sphingolipids, being principle
constituents of membrane lateral microdomains, were found to
be important for CaCdr1p localization. Since the disruption of
ergosterol and sphingolipid biosynthetic genes lead to mislo-
calization of CaCdr1p, it should be noted that the observed
poor efflux of drugs mediated by CaCdr1p and the enhanced
drug sensitivity of null mutants were mainly due to this mislo-
calization instead of its impaired functioning.
A recent proteomic analysis of DRMs from C. albicans iden-
tified 29 proteins to be localized within membrane rafts (22). In
that study, CaCdr1p was not detected in DRMs, which could
have been due to the poor level of expression of CaCdr1p in
the laboratory isolate SC5314. Some other known raft proteins
including amino acid permease Fur4p, Tat2p, and transporters
Can1p and Nce2p were also not detected in that study (22).
FIG. 8. Isolation of DRMs from yeast. (A) Schematic of the gradient, illustrating the concentration of Optiprep in each step. (B) Proteins
isolated from six gradient fractions, separated by SDS-PAGE. (C) Immunoblot of Pma1p with -Pma1p primary polyclonal antibody which was
detected with horseradish peroxidase-conjugated secondary antibody, followed by detection of chemiluminescence (ECL kit; Amersham) (43) to
confirm raft preparation. (D) Immunoblot of gradient fractions of CaCdr1p with -GFP monoclonal primary antibody in the wild-type (WT)
(upper panel), detected with horseradish peroxidase-conjugated secondary antibody in sphingolipid mutants sur4, fen1, and ipt1 and ergosterol
mutants erg6, erg24, or erg4 expressing CaCdr1p-GFP. (E) Immunoblot of gradient fractions of CaMdr1p with -GFP monoclonal antibody
in the wild type (upper panel), sphingolipid mutants sur4, fen1, and ipt1, and ergosterol mutants erg6, erg24, and erg4 expressing
CaMdr1p-GFP.
702 PASRIJA ET AL. ANTIMICROB. AGENTS CHEMOTHER.
The expression of the protein in a heterologous background
probably does not affect its association with the raft, as Hup1p
of Chlorella kessleri, which exclusively exists in rafts, when
expressed in S. cerevisiae, still retained its property of being
localized within the DRM microdomains (20). Interestingly,
only certain proteins are localized within DRMs. Yeast PM-
ATPase is one such example, which is exclusively found within
rafts. The oligomerization of Pma1p has been linked to mem-
brane lipid composition, since in ceramide-depleted cells,
Pma1p remains monomeric (27). Our present study also con-
firms that, similar to CaCdr1p, the PM-ATPase protein is
localized within rafts and is mistargeted in lipid mutant back-
grounds (data not shown). Although, it would seem logical to
predict the localization of proton-generating (Pma1p) and -uti-
lizing (CaMdr1p) proteins within the same membrane lateral
domains, our study demonstrates that this is not the case and
apparently tight coupling between proton motive force-gener-
ating Pma1p and proton motive force-dissipating CaMdr1p is
not obligatory.
The association of certain proteins with a raft has emerged
as an important regulator of signal transduction, protein- and
membrane-polarized intracellular sorting, cytoskeletal reorga-
nization, and entry of infectious organisms in living cells (23).
In C. albicans, glycosylphosphatidylinositol-anchored proteins
Eap1p, Dfg5p, and Phr1p are present in DRMs and are known
to be involved in adhesion to epithelial cells, virulence, and
proper hyphal growth (29). Gas1p from S. cerevisiae is involved
in cell wall biogenesis and is a known lipid raft protein (1, 3,
29). The functional significance of the PM compartmentaliza-
tion is evident by the protein distribution in polarized, mating-
induced Schizosaccharomyces pombe cells and in S. cerevisiae,
which harbors proteins in the shmoo that are required for
mating (3, 46). The hyphal tips of C. albicans also show ergos-
terol-enriched domains, which may be indicative of clustering
of DRMs in its growing tip (29). We had previously observed
that CaCDR1 is highly expressed during hyphal development
in C. albicans cells (14). With this background, it is tempting to
speculate that if CaCdr1p is also localized on growing hyphal
tips then it may have a role in the morphogenesis of Candida
as well. It may not be out of context to mention that most of the
transcription factors regulating C. albicans morphogenesis also
regulate CaCDR1 (33). In this context, the role of rafts as a hub
of signaling in Candida cells remains to be examined.
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